Lead
Hims & Hers Health ($HUM) stock plummeted 12% following disappointing first-quarter earnings results that fell short of Wall Street expectations on both the top and bottom lines. The telehealth provider reported a $0.40 loss per share against analyst forecasts of a $0.01 profit, while revenue came in at $608 million compared to the expected $616.5 million. The miss marked a rare stumble for the fast-growing digital health company, which has emerged as one of the sector's most compelling growth stories in recent years.
Yet beneath the disappointing quarterly performance lies a more nuanced narrative. Management raised its full-year 2024 sales guidance to $2.8-3 billion, signaling confidence in the company's medium-term trajectory despite near-term headwinds. More striking still, Hims & Hers projects revenues could reach $6.5 billion by 2030, suggesting the company believes it remains on track for substantial expansion. The divergence between Q1's miss and management's bullish forward guidance has left investors grappling with competing signals about the company's near and long-term prospects.
Key Details: The Earnings Miss and Strategic Pivot
The first-quarter shortfall appears rooted in broader operational and strategic headwinds affecting the telehealth sector. Hims & Hers missed revenue expectations by approximately 1.4% ($8.5 million shortfall), a relatively modest gap that nonetheless triggered sharp market repricing. The earnings per share miss was far more pronounced, with the company's $0.40 loss falling $0.41 short of the forecasted breakeven profit—a dramatic swing that suggests margin pressures are weighing on profitability.
However, the company's forward guidance suggests management believes the worst may be behind it:
- Full-year 2024 revenue guidance: $2.8-3 billion (raised from prior expectations)
- 2030 revenue projection: $6.5 billion (implying compound annual growth of roughly 22% over six years)
- Geographic expansion: Entering new markets to drive incremental revenue
- Product diversification: Expanding beyond traditional telehealth into additional drug categories
- GLP-1 strategy shift: Moving toward reselling branded products from major pharmaceutical manufacturers
The shift in GLP-1 strategy represents a particularly significant pivot. Rather than pursuing direct manufacturing or private-label versions of glucagon-like peptide-1 drugs—the blockbuster weight-loss and diabetes medications driving outsized enthusiasm in digital health—Hims & Hers is pivoting to a reseller model for branded products from established pharmaceutical companies. This approach reduces capital intensity and regulatory complexity but may also cap margin upside compared to proprietary formulations.
Market Context: Sector Headwinds and Competitive Pressures
The telehealth sector has faced intensifying headwinds throughout 2024, with several factors converging to constrain growth and profitability. The initial euphoria surrounding GLP-1 drugs—which promised massive addressable markets for weight loss and metabolic health—has given way to a more realistic assessment of competitive dynamics and reimbursement challenges.
Hims & Hers operates in an increasingly crowded competitive landscape:
- Amazon's expansion into pharmacy and telehealth through partnerships and acquisitions
- Ro and other venture-backed telehealth platforms competing aggressively on GLP-1 offerings
- Traditional pharmacy chains like CVS ($CVS) and Walgreens ($WBA) leveraging existing infrastructure and patient relationships
- Major healthcare systems vertically integrating telehealth capabilities
Regulatory scrutiny has also intensified. The FDA and state medical boards have imposed stricter requirements around telehealth prescribing, particularly for controlled substances and high-demand medications like GLP-1 drugs. These requirements increase operational complexity and customer acquisition costs while potentially limiting market addressability.
The company's decision to shift toward reselling branded GLP-1 products rather than proprietary formulations reflects this reality. Competing against pharmaceutical giants' branded products requires accepting lower margins but may provide greater regulatory clarity and market acceptance compared to alternative formulations.
Investor Implications: Reading Between the Lines
The market's sharp 12% reaction to Q1 earnings reflects broader uncertainty about Hims & Hers' profitability trajectory and competitive positioning. Several key questions now occupy investor minds:
Margin sustainability: The company reported a per-share loss in Q1, suggesting ongoing path-to-profitability challenges. While raising full-year guidance suggests management confidence, investors will scrutinize whether the company can achieve positive unit economics at scale without sacrificing market share. The shift to branded GLP-1 reselling may provide margin relief but at the cost of competitive differentiation.
Growth deceleration risks: The 2030 revenue projection of $6.5 billion implies growth that, while respectable, is notably more measured than projections made by the company in prior years when GLP-1 enthusiasm peaked. This suggests management may be tempering expectations in light of current market realities.
Capital efficiency: Telehealth companies require substantial marketing spend to acquire customers in an increasingly competitive environment. Hims & Hers' ability to achieve positive free cash flow while maintaining growth rates will determine long-term investor appeal. The company's shift toward reselling rather than manufacturing reduces capital intensity but may limit upside potential.
Market maturation: The Q1 miss suggests that telehealth growth rates may be moderating as the category matures. This is particularly relevant for investors who viewed Hims & Hers as a high-growth play. The company's transition toward stable, profitable growth may be inevitable but could disappoint momentum-driven investors expecting consistent acceleration.
For long-term investors focused on value creation, the combination of a near-term miss with improved full-year guidance and bold 2030 projections may present a buying opportunity, particularly if the stock sell-off has been overdone. Conversely, investors seeking near-term profitability improvement or aggressive top-line acceleration may find better opportunities elsewhere in the healthcare or consumer sectors.
Looking Ahead: The 2024-2030 Evolution
Hims & Hers finds itself at a critical juncture. The company has successfully scaled to become a meaningful player in telehealth, but the era of explosive growth may be transitioning toward more sustainable but slower expansion. Management's willingness to raise full-year guidance despite a Q1 miss suggests conviction in the underlying business trajectory, but execution risk remains elevated.
The path to $6.5 billion in revenue by 2030 will require successful execution across multiple dimensions: geographic expansion to untapped markets, deepening penetration in existing categories, and establishing durable competitive advantages in an increasingly crowded space. The shift toward branded GLP-1 reselling is pragmatic but highlights the challenges of competing against pharmaceutical giants in highly regulated, capital-intensive markets.
Investors should monitor upcoming quarterly results closely for evidence of stabilizing margins, accelerating growth, or both. The telehealth sector remains structurally attractive given aging demographics and shifting consumer preferences toward digital health, but individual company success is far from assured. Hims & Hers has proven execution capability, but the market's 12% reaction underscores that investors are increasingly demanding evidence of sustainable profitability, not merely revenue growth.